Seattle Low Vision’s Dr. Ross Cusic Highlights Resources for Visually Disabled Washingtonians Ahead of December

As Gift of Sight Month (December) and International Day of Persons with Disabilities (December 3rd) draw near, Dr. Ross Cusic, Clinical Director at Seattle Low Vision and an outspoken advocate for visually disabled individuals, is intensifying his campaign to raise awareness about the critical gaps in care affecting this community.

According to the study published in Optometry and Vision Science, over 90% of visually disabled people are not referred to necessary resources and care, deeply impacting their daily lives and the well-being of their families. This issue affects 4% of Washington state’s population, predominantly senior citizens, leaving thousands without the support they need to lead independent lives.

                                                                   

Dr. Cusic, a charter member of the International Academy of Low Vision Specialists and current chair of the Optometric Physicians of Washington’s low vision committee, is leading a campaign to address this critical issue. “Many people with low vision are unaware of the support available to them, and that must change,” says Dr. Cusic. “Our goal is to ensure these people, often senior citizens, can regain their independence and live their best lives.”

Seattle Low Vision specializes in customized low vision care, providing patients with prescription glasses and other vital tools. Dr. Cusic's patients, most of whom are elderly and dealing with conditions like macular degeneration and diabetic retinopathy, can once again engage in activities they thought were lost to them, from watching television to seeing their family members.

To further support Washington’s visually disabled population, Dr. Cusic offers a free Washington Low Vision Guide and complimentary phone consultations to assist those in need. By empowering visually impaired individuals, Seattle Low Vision not only improves lives but also eases the burden on families who care for their loved ones.

For more information or to connect with Dr. Cusic, and patients, or to learn more about Seattle Low Vision’s approach, visit www.seattlelowvision.com or contact the clinic directly.

About Seattle Low Vision:

Seattle Low Vision, a low vision optometric practice that changes people's lives. It is dedicated to improving the lives of people with severe vision impairments. Through personalized low vision care, including prescription bioptic telescope glasses and other tools, the clinic helps patients regain their independence and enhance their quality of life.

Media Contact
Company Name: Seattle Low Vision
Contact Person: Dr. Ross Cusic
Email:Send Email
Phone: (425) 823-2020
Address:12911 120th Ave NE G105
City: Kirkland
State: WA 98034
Country: United States
Website: www.seattlelowvision.com

2024 Election Watch Party: Community Gathers for Election Night at Harlem State Office Building Plaza

November 5, 2024 - We are excited to celebrate and participate in the democratic process with a special Election Watch Party hosted on Tuesday, November 5, 2024, at the Harlem State Office Building Plaza, located at 163 W. 125th St., New York, from 8:00 p.m. to midnight.  This promises to be an inspiring evening with the community come together to witness the 2024 election results unfold. 

Key organizers include: C. Virginia Fields, Hazel Dukes, Deneane Brown-Blackmon, Michelle Hardy, Athena Moore, and Madisen Gray. Together, they have coordinated with numerous local organizations to ensure the event is inclusive, accessible, and reflective of Harlem’s unique spirit of unity and resilience.

As we watch the election results, attendees can engage with our political figures and organization sponsors.  Includes NYS Senator Cordell Cleare, NYS Assembly Member Inez Dickens, Congressman Adriano Espaillat, Manhattan Borough President Mark Levine, NY County Leader Keith Wright, City Councilman Yusef Salaam, NYS Assembly Candidate Jordan Wright, NAACP New York and Mid-Manhattan branches, Harlem Congregations for Community Improvement, Alpha Kappa Alpha Sorority, Inc., Tau Omega Chapter, Omega Psi Phi Fraternity, Inc., Xi Phi Chapter, the Jack and Jill of America Metropolitan Chapter, Stroll to the Polls, The Beat 139 Media, the New York and National Urban Leagues, and real estate advisor Ed Poteat,

Special thanks to our Community Partners that share a mission of fostering civic involvement and public awareness. The Links, Inc. Greater New York Chapter, Central Harlem Senior Citizens Center, and Community Board 10, and CUNY Graduate School of Public Health & Policy.

The Election Watch Party embodies Harlem’s commitment to civic participation and community solidarity.

For more information about at this year’s Election Watch Party, please contact event organizer, C. Virginia Fields at 917-558-3475.

Media Contact
Company Name: C. Virginia Fields
Contact Person: C. Virginia Fields
Email:Send Email
Phone: 917-558-3475
Country: United States
Website: https://www.fiverr.com/presguy/do-press-release-distribution-in-24hrs

Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Ovarian Cancer Pipeline Insight 2024” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Ovarian Cancer Research. Learn more about our innovative pipeline today! @ Ovarian Cancer Pipeline Outlook

 

Key Takeaways from the Ovarian Cancer Pipeline Report

• In November 2024;- Dana-Farber Cancer Institute- This is an open-label, single site, phase 1b study to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer. Participants will be enrolled to test the safety of intraperitoneal CIML NK cell therapy. The U.S. Food and Drug Administration (FDA) has not approved CIML NK cell therapy as a treatment for recurrent, high grade ovarian cancer.
• In October 2024:- Tesaro Inc.- This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
• In October 2024:- Takeda- The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple times. In both phases, the participants will receive TAK-853 on the first days of each 3-week cycle.
• In October 2024:- Theolytics Limited- A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer. The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will also aim to establish if THEO-260 is able to treat ovarian cancer.
• DelveInsight’s Ovarian Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.
• The leading Ovarian Cancer Companies such as Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
• Promising Ovarian Cancer Therapies such as SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others. 

 

Stay informed about the cutting-edge advancements in Ovarian Cancer treatments. Download for updates and be a part of the revolution in care @ Ovarian Cancer Clinical Trials Assessment

 

Ovarian Cancer Emerging Drugs Profile

• Atezolizumab: Genentech

Atezolizumab is a humanized kappa immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster ovary cells. Atezolizumab was engineered to eliminate Fc-effector function via a single amino acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-glycosylated antibody that has minimal binding to Fc receptors and, consequently, eliminates detectable Fc-effector function and depletion of cells expressing programmed death−ligand 1 (PD-L1) in humans. Atezolizumab targets human PD-L1 and inhibits its interaction with its receptors, programmed death−1 (PD-1) and B7.1, both of which can provide inhibitory signals to T cells. The drug is currently in phase 3 of clinical trials for the treatment of Ovarian Cancer.

• Tisotumab Vedotin: Genmab

Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. The drug is currently in phase 2 of clinical trials for the treatment of Ovarian Cancer.

• SON-1010: Sonnet Biotherapeutics

SON-1010 is a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform, which targets the tumor microenvironment (TME) and extends the pharmacokinetics (PK) and subsequent pharmacodynamics (PD) of the molecule. Sonnet and Roche have entered into a Master Clinical Trial and Supply Agreement (MCSA), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (PROC) patient setting. Currently the drug is in the Phase I/II stage of its development for the treatment of ovarian cancer.

• DS-6000a: Daiichi Sankyo Company

DS-6000a is an antibody-drug conjugate, comprised of an humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I (TOP1) inhibitor payload via a cleavable linker. DS-6000a specifically binds to CDH6 on the surface of tumor cells and is internalized upon binding. The payload is then released, resulting in target cell apoptosis. In preclinical studies, DS-6000a inhibited tumor growth and induced tumor regression in CDH6-expressing RCC and OVC. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Ovarian Cancer.

  

Learn more about Ovarian Cancer Drugs opportunities in our groundbreaking Ovarian Cancer Research and development projects @ Ovarian Cancer Unmet Needs

 

Ovarian Cancer Companies

Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.

 

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Ovarian Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Discover the latest advancements in Ovarian Cancer treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Ovarian Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Ovarian Cancer Pipeline Report

• Coverage- Global
• Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ovarian Cancer Companies- Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
• Ovarian Cancer Therapies- SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.

 

For a detailed overview of our latest research findings and future plans, read the full details of Ovarian Cancer Pipeline on our website @ Ovarian Cancer Emerging Drugs and Companies

 

 Table of Content

1. Introduction
2. Executive Summary
3. Ovarian Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ovarian Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Tisotumab Vedotin: Genmab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DS-6000a: Daiichi Sankyo Company
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ovarian Cancer Key Companies
21. Ovarian Cancer Key Products
22. Ovarian Cancer- Unmet Needs
23. Ovarian Cancer- Market Drivers and Barriers
24. Ovarian Cancer- Future Perspectives and Conclusion
25. Ovarian Cancer Analyst Views
26. Ovarian Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

The Sale of Malaysia Crawler Excavator Market to Reach 3.44 Thousand Units by 2029, Generating Over $175.6 Million Revenue in the Next Six Years - Arizton

Malaysia Crawler Excavator Market Research Report by Arizton

The Industry Analysis Report Provides Industry Trends, Drivers, Opportunities, Competitive Outlook, Market Size, Sales, and Growth Forecast for 2024-2029

According to Arizton’s latest research report, the Malaysia crawler excavator market is growing at a CAGR of 5% during 2023-2029.

         

Looking for More Information? Click: https://www.arizton.com/market-reports/malaysia-crawler-excavator-market-strategic-assessment-forecast

 

Report Scope:         

Market Size – Volume (2029): 3.44 thousand Units          

Market Size – Volume (2023): 2.56 thousand Units              

CAGR (2023-2029): 5%     

Market Size – Revenue (2029): USD 175.6 Million           

Historic Year:  2020-2022                 

Base Year: 2023                 

Forecast Year: 2024-2029                 

Market Segmentation: Size, Gross Power, and End Users

         

The crawler excavator market in Malaysia is projected to reach $175.6 million by 2029. Chinese construction machinery brands are shifting their strategy from solely exporting products to establishing localized operations in Southeast Asia. Notable companies like Zoomlion and SANY have recently opened subsidiaries in Malaysia, Vietnam, and the Philippines, underscoring their commitment to local development. In a significant project, a fleet of 10 EC550EL excavators from Volvo Construction Equipment (Volvo CE) is currently being utilized to construct a large new dairy farm for Fraser & Neave Holdings (F&N) in Gemas, Negeri Sembilan, Malaysia.

In 2024, Ponterosso Technics Sdn Bhd expanded its operations by purchasing seven excavators, including Cat 352 and Cat 333 models.

Volvo has also upgraded the cab design of its new excavators, integrating a human-machine interface (HMI) that automates boom and bucket movements through the Volvo Active Control machine control system. This enhancement, paired with an electric control joystick, offers operators improved support at job sites. Additionally, in 2024, Komatsu acquired all shares of UMW Corporation Sdn. Bhd. (United Motor Works), making UMW Komatsu Heavy Equipment Sdn. Bhd. (UKHE) a wholly owned subsidiary. This acquisition aims to strengthen Komatsu's competitiveness in the construction and mining equipment market in Malaysia. Volvo Construction Equipment also received orders for seven excavators from three different customers in Malaysia in 2024. AAY Construction Sdn. Bhd. ordered four EC550EL excavators, while TCT Success Sdn. Bhd. ordered EC480DL models, and Sempurna Akuatik ordered EC220DL and EC350DL models. The EC550EL, EC200D, and EC350DL are particularly popular in the Malaysia market.

 

Addressing Malaysia's Waste Challenge: Initiatives and Opportunities for Mini Excavators

Malaysia generates over 39,000 tons of municipal solid waste each day, with food waste accounting for more than 30% of this total volume. This concerning level of waste is largely driven by changing lifestyles, population growth, and rapid urbanization.

Currently, there are 165 operational landfills across Malaysia for waste management. The government has set an ambitious target to achieve a 40% recycling rate by 2025. To support this goal, plans are underway to construct six waste-to-energy plants that will convert waste into energy, helping to reduce the volume of waste disposed of in landfills, which poses significant environmental challenges.

In 2024, the Ministry of Housing and Local Government identified 18 sites nationwide for the development of these waste-to-energy plants. Additionally, the government has allocated $2.7 million to various waste-to-energy projects across the country.

As waste management activities surge in response to these initiatives, the demand for mini excavators in the Malaysian market is expected to increase, highlighting the growing need for efficient machinery in waste handling and recycling operations.

 

Looking for More Information? Click: https://www.arizton.com/market-reports/malaysia-crawler-excavator-market-strategic-assessment-forecast

 

Malaysia Crawler Excavator Market Dynamics

DRIVERS

Surge In Infrastructure Investment

Growing Investment in Transport Sector

Investment in Renewable Energy Sector

TRENDS

Growing Use of Modern Excavators

Surge Demand for Mini Excavators in Waste Management

Use of Low Fuel Consumption Excavators

CHALLENGES

Increased Construction Costs

Shortage of Skilled Labor

Low Quality Construction Projects

 

Prominent Vendors

• Caterpillar
• Komatsu
• Xuzhou Construction Machinery Group (XCMG)
• SANY
• Zoomlion Heavy Industry Science&Technology Co., Ltd.
• Volvo Construction Equipment
• Hitachi Construction Machinery
• Kobelco
• Hyundai Construction Equipment
• JCB
• Kubota
• CASE Construction Equipment
• LiuGong
• DEVELON
• Bobcat
• Sunward Intelligent Equipment Group
• Mecalac
• SDLG

 

Distributor Profiles

• Sunway Marketing Sdn Bhd
• UMW Equipment Sdn. Bhd.
• TCIM
• UM Construction Equipment Sdn Bhd
• WDG RESOURCES Sdn Bhd
• KS Kim Sui Engineering Sdn Bhd
• Multico (M) Sdn Bhd

 

Market Segmentation Crawler Excavator

 

Size

• Mini Excavator
• Small Excavator
• Medium Excavator
• Large Excavator

 

Gross Power

• Less Than 60 HP
• 60 HP -100 HP
• 101 HP-200 HP
• Above 200 HP

 

End Users

• Construction
• Mining
• Agriculture
• Forestry
• Others (Power Generation, Utilities Municipal Corporations, Oil & Gas, Cargo Handling, Power Generation Plants, Waste Management)

 

In a nutshell, the Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the Malaysia crawler excavator market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/malaysia-crawler-excavator-market-strategic-assessment-forecast

         

What Key Findings Will Our Research Analysis Reveal?       

How big is the Malaysia crawler excavator market?

What is the growth rate of the Malaysia crawler excavator market?

Who are the key players in the Malaysia crawler excavator market?

What are the trends in the Malaysia crawler excavator industry?

Which are the major distributor companies in the Malaysia crawler excavator market?

   

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4556 

 

Other Related Reports that Might be of Your Business Requirement       

Thailand Crawler Excavator Market - Strategic Assessment & Forecast 2024-2029

https://www.arizton.com/market-reports/thailand-crawler-excavator-market-strategic-assessment-forecast

Vietnam Crawler Excavator Market - Strategic Assessment & Forecast 2024-2029

https://www.arizton.com/market-reports/vietnam-crawler-excavator-market-opportunities-assessment-forecast

 

Why Arizton?                                                  

100% Customer Satisfaction                                                  

24x7 availability – we are always there when you need us                                                  

200+ Fortune 500 Companies trust Arizton's report                                                  

80% of our reports are exclusive and first in the industry                                                  

100% more data and analysis                                                  

1500+ reports published till date                                

                     

Post-Purchase Benefit                                              

• 1hr of free analyst discussion                                              
• 10% off on customization                           

                    

About Us:                                                                                       

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                     

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                      

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                            

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email:Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/malaysia-crawler-excavator-market-strategic-assessment-forecast

Surface Radars Market worth $22.49 Billion by 2029, at a CAGR of 5.4%

Surface Radars Market

The global Surface Radars Market in terms of revenue is estimated to be worth $17.26 billion in 2024 and is poised to reach $22.49 billion by 2029, growing at a CAGR of 5.4% during the forecast period.

The report "Surface Radars Market by Platform (Critical Infrastructure, Vehicle-Mounted, Shipborne, Unmanned Surface Vehicles), Application (Surveillance, Air-Defense, Perimeter Security, Battlefield ISR), Frequency Band, Dimension - Global Forecast to 2029" The global surface radars market is projected to reach USD 22.49 billion by 2029, from USD 17.26 billion in 2024, at a CAGR of 5.4%. The volume of surface radars is projected to grow from 4690 (in Units) in 2024 to 6113 (in Units) by 2029. Due to the currently existing conflicts and security threats that cross borders, governments are fortifying their defense capabilities, but most significantly in air defense, maritime surveillance, and critical infrastructure protection. Advanced radar systems are mainly important features of modern military operations because of high precision detection and tracking capabilities and integration with command and control systems.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=244541997

Browse 300 market data Tables and 80 Figures spread through 380 Pages and in-depth TOC on "Surface Radars Market"

View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/surface-radars-market-244541997.html

Beyond these security requirements, developments related to radar systems, which include the Advanced Electronically Scanned Array (AESA) radars and AI-powered systems, are altering the very character of performance that ought to enhance the effectiveness of identification systems with respect to stealth aircraft, missiles, and other state-of-the-art threats. Further advancement of technological feature is driving the demand of surface radars. Major players in the market are investing in research and developments to create advanced radar systems for strength market position worldwide but major concentration geographically is North America, Europe, Asia Pacific, and the Middle East.

Based on platform, the shipborne segment is estimated to capture largest share in the market during the forecast period

The shipborne segment is estimated to capture largest share during the forecast period. The surface radar market, during the forecast period, is poised to gain the largest market share through its shipborne segment. The primary growth factor is the increasing focus on maritime security and naval modernization. With rising threats in international waters, including piracy, illegal fishing, and territorial disputes, governments are investing heavily in upgrading their naval fleets with advanced radar systems. Asia-Pacific and the Middle East are the regions where several countries are spending money in modern shipborne radar systems to secure their naval assets. Some of the newer applications are shipborne radar use for ballistic missile defense and coastal surveillance.

Based on range, the short-range segment is forecasted to grow at highest CAGR during forecast period

The short range segment is forecasted to grow at the highest CAGR during the forecast period. In this forecast period, the short range radar is expected to grow at the highest CAGR due to increasing utilization in tactical operations and urban warfare environments. These are crucial for border security and air defense plus counter-drone operations. Since both urban and asymmetrical warfare remain central to the battles of today, short-range radars are well-suited for real-time surveillance capabilities in high-contest areas. The proliferation of UAVs and drone technology also calls for the provision of short-range radars so that detection and neutralization of threats at low altitude may take place effectively. The short-range radar systems are also finding a wider scope of civilian applications, such as monitoring traffic and disaster management besides military applications. 

Asia-Pacific is expected to capture the largest share during the forecast period in 2024.

The surface radars market in APAC is expected to lead in 2024. The Asia-Pacific region, with its huge increase in defense budgets fueled by raised geopolitical tensions and territorial disputes, is likely to capture the largest share of the surface radar market. Countries like China, India, Japan, and South Korea are majorly investing in advanced radar systems to strengthen their air and missile defenses, especially in the context of regional threats in the South China Sea and East Asia. The Asia-Pacific region is also experiencing an all-around military modernization wherein surface radars play a critical role in the monitoring of airspace and border protection, as well as maritime surveillance. The indigenous defense capability of the region further fuels the need for developing advanced radar systems. With all the efforts towards smart cities and infrastructure development in Asia-Pacific countries such as Japan, the requirements of civil surveillance and urban security propel radar systems' deployment.

All those segments and regions have drivers and restraints traceable back to either technological advancement or strategic defense requirements and, in aggregate, serve growth for the surface radar sector.

Key players in the surface radars market are Lockheed Martin Corporation (US), RTX (US), BAE Systems (UK), Northrop Grumman (US), Israel Aerospace Industries (Israel), Thales (France), Saab AB (Sweden), Elbit Systems Ltd. (Israel), Northrop Grumman (US), Aselsan A.S (Turkey), Bharat Electronics Limited (BEL) (India) Leonardo S.p.A.(Italy),  L3Harris Technologies, Inc. (US), Indra (Spain), Teledyne FLIR LLC (US), and Hensoldt (Germany), These players have adopted various growth strategies to expand their presence in the surface radars market.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/surface-radars-market-244541997.html

Level Sensor Market worth $7.64 Billion in 2029, at a CAGR of 6.5%

Level Sensor Market

The global Level Sensor Market in terms of revenue is estimated to be worth $5.56 billion in 2024 and is poised to reach $7.64 billion in 2029, growing at a CAGR of 6.5% during the forecast period.

The report "Level Sensor Market by Type (Magnetostrictive, Vibratory Probe, Hydrostatic, Magnetic & Mechanical Float, Pneumatic, Guided Wave, Ultrasonic, Microwave, Optical, Capacitance Level Sensors), Sensor Type (Contact, Non-contact) - Global Forecast to 2029" The global level sensors industry size is projected to reach USD 7.64 billion in 2029 from USD 5.56 billion in 2024, with a CAGR of 6.5%.

Level sensor market growth is mainly fueled by the increasing demand for accurate and reliable level measurements in several manufacturing-related industries, as well as oil and gas, chemicals, and food and beverages. In addition, the growing adoption of automation, and initiatives under Industry 4.0, accompanied by increased demand for improved process efficiency and safety, will further drive the demand for advanced-level sensing technologies. With the mounting focus on environmental monitoring and sustainability, industries are adopting advanced-level sensors for resource management and environmental compliance.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=926

Browse 160 market data Tables and 60 Figures spread through 285 Pages and in-depth TOC on "Level Sensor Industry"

View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/level-sensors-market-926.html

Contact level sensors are projected to maintain a significant CAGR in the global level sensor industry during the forecast period.

Contact level sensors is expected to account for a significant growth rate in the global level sensor industry during the entire forecast period. This is due to their efficiencies in many industrial applications. Such sensors operate by directly making contact with the liquid or solid to be measured, to achieve precise measurements of levels, leaks, and flow rates. Their reliability, cost-effectiveness, and ability to function well in challenging environments like high temperatures or pressures make them perfect fits for industries like oil & gas, water & wastewater, and chemicals. Even though non-contact alternatives are increasing in popularity, contact sensors are still preferred due to the proven track record of performance at achieving accurate and uninterrupted level monitoring in the application.

Magnetic and Mechanical Float level sensors are expected to capture a significant share in the global market during the forecast period.

Magnetic and mechanical float level sensors are expected to capture a significant share of the market during the forecast period. These sensors work on float principle, where the float rises or falls with the liquid level, thus triggering a magnetic or mechanical switch indicating the level. It is ideal for those water & wastewater, oil & gas, and chemical processing industrial applications where very accurate monitoring of level is necessary. Its rugged design and the ability to operate well under harsh environments also support continued demand in many diverse applications. The high growth rate of automation will also boost the need for such proven technologies.

Continuous level monitoring is projected to hold the largest share in the global level sensor industry during the forecast period.

During the forecast period, continuous level monitoring will maintain the largest share in the level sensor industry since it can offer real-time, accurate measurement of liquid or solid levels over a long range. In contrast to point level sensors, which report only at a specific threshold being achieved, continuous level sensors track the entire range of levels. Continuous level sensors are more useful where precise level maintenance is absolutely necessary like in applications involving chemical processing, water treatment, or food production. Their ability to provide real time updates increases operational efficiencies, reduces downtime, and supports automated systems that require constant feedback about the material level. With the rising adoption of automation and smart manufacturing, the demand for this solution is expected to increase dramatically and that would further cement its position as a critical segment of the level sensor industry.

Liquid level sensors are projected to capture the highest share in the global level sensor industry during the forecast period.

By application liquid level sensors are projected to capture the highest share of the level sensor industry. Liquid applications require precise monitoring of liquid levels for both safety and process efficiency reasons and to ensure compliance with regulatory procedures. For example, reliable liquid-level sensors enable consistent product quality in food production and ensure optimal levels of water inside a wastewater plant. Advancements in wireless communication and further integration with IoT have been adding to the development of liquid level monitoring. The demand for liquid-level sensors is likely to grow in the coming years, driven by increasing automation and real-time analytics.

The pharmaceuticals sector is expected to experience significant growth in the level sensor industry during the forecast period.

The pharmaceutical industry is expected to grow at a significant CAGR in the level sensor industry over the forecast period. There is an increasing demand for the measurement of levels during critical processes such as drug formulation, fluids, and chemical storage. Level sensors play an extremely significant role in the pharmaceutical environment to ensure safety and compliance with strict regulatory standards to ensure that the product is of high quality. Implementation of automation and in-line monitoring will highly contribute to increased operational efficiency and reduced risks of contamination, thus increasing the demand for higher-grade sensors. Also, pharmaceutical production will further benefit from IoT and smart manufacturing technologies through improvement in the growth of level sensors.

Asia Pacific to capture the highest share in the global level sensor industry during the forecast period.

The Asia-Pacific region is expected to lead the level sensors industry during the forecast period. The tremendous growth is catalyzed by rapid industrialization, positive influences in manufacturing activities, and on-ground adoption of automation technologies across various process industries. In this region, industries like automotive, pharmaceuticals, chemicals, and water & wastewater management have expanded levels of dependency on precise level monitoring to enhance operational efficiency and meet standards defined by regulations. Besides, smart manufacturing and the support of IoT will increase the adoption of level sensors. As industrial automation and infrastructure investment is picking up demand for level sensors, in Asia Pacific, is likely to be increase.

Major companies operating in the level sensors industry include ABB  (Switzerland), Emerson Electric Co. (US), AMETEK.Inc. (US), Siemens (Germany), and Honeywell International Inc. (US).

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/level-sensors-market-926.html

FundedTigers Launches to Empower Forex Traders with Virtual Capital Funding

FundedTigers, a newly launched proprietary trading firm tailored for forex and high-frequency traders (HFT), is reshaping the funding landscape by providing traders with the opportunity to pass evaluations, access virtual capital, and earn real payouts.

FundedTigers supports both forex and HFT traders, enabling them to showcase their trading skills through rigorous evaluations. Successful traders gain access to virtual capital, allowing them to trade without personal financial risk. With a team of industry experts and an unwavering commitment to quality, FundedTigers is redefining funding solutions for traders worldwide.

"We’re excited to bring FundedTigers to the industry as a firm that not only supports forex traders but also welcomes HFT strategies," said the CEO of FundedTigers and an established professional gold trader. "Our mission is to be the preferred funding provider for all traders, and our dedication to quality and client success sets us apart."

Offering a range of account options, competitive pricing, and account merges up to $500,000, FundedTigers leverages cutting-edge technology to deliver optimal trading conditions. With the motto "Built by Traders, for Traders," FundedTigers is committed to continuously enhancing its services to support both forex and high-frequency traders in achieving their funding goals.

"We recognize that each trader has unique needs, especially in high-frequency trading, and we’re here to provide customized solutions that enable them to excel," said the CEO of FundedTigers.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: FundedTigers
Email:Send Email
Country: Lithuania
Website: https://fundedtigers.com/

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Relapsed/Refractory Acute Myeloid Leukemia Research. Learn more about our innovative pipeline today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook

 

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

• In November 2024:- Roswell Park Cancer Institute- This phase I/Ib trial studies the side effects and best dose of talazoparib given together with gemtuzumab ozogamicin and to see how well they work in treating patients with CD33 positive acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Talazoparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Gemtuzumab ozogamicin is a protein (antibody) combined with a chemotherapy drug which specifically targets acute myeloid leukemia cells expressing a marker (CD33). Adding talazoparib to the gemtuzumab ozogamicin therapy may lead to an increased effectiveness in treatment.
• In October 2024:- Astellas Pharma- The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and to determine the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants.
• In October 2024:- Sanofi- An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
• In October 2024:- Apollo Therapeutics Ltd- A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination With Azacitidine in Adults With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB)
• In October 2024:- Ryvu Therapeutics SA- The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2
• DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
• The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Promising Relapsed/Refractory Acute Myeloid Leukemia Therapies such as UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.

 

Stay informed about the cutting-edge advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatments. Download for updates and be a part of the revolution in care @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials Assessment

 

Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile

• APG-2575: Ascentage Pharma

APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).

• CLN 049: Cullinan Oncology

CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.

• Lanraplenib: Kronos Bio

Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.

 

Learn more about Relapsed/Refractory Acute Myeloid Leukemia Drugs opportunities in our groundbreaking Relapsed/Refractory Acute Myeloid Leukemia Research and development projects @ Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs

 

Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Discover the latest advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives

 

Relapsed/Refractory Acute Myeloid Leukemia Market Drivers

• Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important
• factors that are fueling the Relapsed/Refractory Acute Myeloid Leukemia Market.

 

Relapsed/Refractory Acute Myeloid Leukemia Market Barriers

• However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Relapsed/Refractory Acute Myeloid Leukemia Market growth.

 

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

• Coverage- Global
• Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapies- UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Relapsed/Refractory Acute Myeloid Leukemia Pipeline on our website @ Relapsed/Refractory Acute Myeloid Leukemia Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Relapsed/refractory acute myeloid leukemia (AML): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsed/refractory acute myeloid leukemia (AML)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. APG-2575: Ascentage Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CLN 049: Cullinan Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
21. Relapsed/refractory acute myeloid leukemia (AML) Key Products
22. Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
23. Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
24. Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
25. Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
26. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Lateral Flow Assay Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and Forecast

The key players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US),and PerkinElmer Inc. (US).

Browse 419 market data Tables and 59 Figures spread through 399 Pages and in-depth TOC on "Lateral Flow Assay Market by Product (Kit, Readers), Application (STI, Covid-19, Hep, TB, Cardiac marker, Pregnancy; Drug abuse, Vet Diaganostic, Food), Sample (Blood, Urine, Saliva), Technique (Sandwich, Competitive), End User - Global Forecast to 2029

The Lateral Flow Assays industry is expected to grow significantly in the near future due to the increasing demand for rapid, portable, and easy-to-use diagnostic tests. Lateral flow assays have already proven to be valuable in a variety of applications, including medical diagnostics, food safety testing, environmental monitoring, and drug testing, among others. Advances in technology and the development of new and more sensitive detection methods are likely to further improve the performance and accuracy of lateral flow assays, making them even more versatile and useful in the years to come.

Lateral Flow Assays Market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027 according to a new report by MarketsandMarkets™. The increasing demand of lateral flow assays due to increase in prevalence of infectious disease, increasing number of geriatric populations in many countries, and rising use of home-based lateral flow assay devices are the major factors driving the growth of this market. On the other hand, reluctance among doctors and patients to change existing diagnostic procedures and the low accuracy of lateral flow assays are the key restraints.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133

Browse in-depth TOC on "Lateral Flow Assays Market"

366 - Tables

58 - Figures

374 - Pages

In this report, the lateral flow assays market is segmented on the basis of product type, application type, technique type, sample type, end user, and region.

"Lateral Flow Readers segment is expected to witness the fastest growth during the forecast period"

Based on product type, the lateral flow assays market is segmented into kits & reagents and lateral flow readers. During the forecast period, this segment is expected to witness the fastest growth during the forecast period. The factors responsible for the growth of this segment are increasing demand of quantitative analysis of clinical sample.

"Veterinary Diagnostics segment accounted for the second largest share of lateral flow assays market in 2021"

Based on applications, the lateral flow assays market is segmented into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing. The veterinary diagnostics segment accounted for the second largest share of the lateral flow assays market in 2021. The possibility of infectious disease outbreaks (particularly in large livestock animals) is driving the demand for lateral flow tests due to their simplicity and rapidity compared to conventional detection methods.

"Multiplex Detection Assays technique is expected to witness the fastest growth during the forecast period"

Based on technique, the lateral flow assay kits & reagents market is segmented into competitive assays, sandwich assays, and multiplex detection assays. The multiplex detection assays technique is expected to witness the fastest growth during the forecast period. The widening scope, applications, and research on multiplex detection assays are expected to boost the growth of this segment in the forecast period.

The lateral flow assays market is segmented into five regions namely North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Asia-Pacific is the second largest region along with fastest growing region of lateral flow assays market owing to major investments in rapid testing in this region.

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133

Lateral Flow Assays Market Dynamics:

Drivers:

1. High prevalence of infectious diseases across the globe
2. Rapidly increasing geriatric population
3. Growing usage of home-based lateral flow assay devices
4. Growing demand for point-of-care testing
5. Need for rapid diagnostic testing for COVID-19

Restraints:

1. Inconsistent results of lateral flow assay tests

Opportunities:

1. Evolving applications of lateral flow assays
2. Rising demand for lateral flow assays in the food & beverage industrya.  Omicron – The new variant of concern is an opportunity for the lateral flow assays marketb.  Government initiatives for omicronc.  Initiatives of Medical diagnostic companies for omicron

Challenges:

1. Limited reimbursements for lateral flow assay products
2. Difficulties in procuring quality raw materials for the development of lateral flow assay tests

Key Market Players:

The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).

Recent Developments:

• In October 2022, F. Hoffmann-La Roche Ltd. (Switzerland) a next-generation portfolio of SARS-CoV-2 rapid antigen test 2.01, SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2, and SARS-CoV-2 Rapid Antigen Test 2.0 Nasal3
• In June 2021, Abbott Laboratories (US) received the CE approval for PanBio Rapid Antigen Self-test, opening access throughout Europe to fast, reliable COVID-19 testing

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=167205133

Lateral Flow Assays Market - Report Highlights:

Refinements in the segments of the lateral flow assays market

The current edition of the report consists of an updated market overview. Additional points in the market overview have been added, keeping in mind the impact of COVID-19 on the overall lateral flow assays market and economic recession impact on lateral flow assays market. Also impact of economic recession on regional market size has been considered in this edition.

Coverage of new market players in the lateral flow assays market

The new edition of the report includes profiles for Oranoxis Inc. (US), AESKU. Diagnostics Gmbh (Germany), Bio Group Medical System (Italy), Pharmact Gmbh (Germany), DIESSE Diagnostica Senese S.P.A (Italy), and Xiamen Biotime Biotechnology Co., Ltd (China).

Updated financial information/product portfolio of players

The new edition of the report provides updated financial information until 2021 for each listed company in a graphical representation as a single diagram (instead of multiple tables). This will easily help analyze the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, business segment focus in terms of the highest revenue-generating segment, and R&D investments.

Updated market developments of profiled players

Recent developments are important to understand market trends and the growth strategies adopted by players. The current edition of this report provides updated developments of profiled players from January 2019 to December 2022, indicating a continuation from the previous version. Product/services launches, approvals, and upgrades, expansions, acquisitions, agreements, partnerships, and collaborations were the principal growth strategies adopted by market players in this period.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/lateral-flow-assay-market-167205133.html

Pioneering Technology Firms Redefine Safety, Hospitality, and Education Standards Through Innovation

MineSafe360, Mjumbex, and Siphiwe Mabusela's Robotics and Coding Academy Lead Transformative Changes Across Key Sectors

A new wave of technology-driven innovation is reshaping industries worldwide, thanks to the groundbreaking work of companies like MineSafe360, Mjumbex, and Siphiwe Mabusela’s Robotics and Coding Academy. These organizations are spearheading advancements in safety solutions, hospitality robotics, and tech education, each bringing unique value to its sector.

MineSafe360 stands at the forefront of safety and environmental monitoring, delivering tailored solutions across diverse industries such as mining, healthcare, education, and public spaces. Offering a comprehensive range of services—from research and development support to mobile application development, API integration, and feature enhancement—MineSafe360 collaborates closely with Original Equipment Manufacturers (OEMs) and Original Design Manufacturers (ODMs) to create customized systems that meet specific client needs. By prioritizing real-time data and efficient, adaptable solutions, MineSafe360 enhances operational safety and environmental protection, solidifying its position as an industry leader.

In the hospitality sector, Mjumbex, founded by visionary entrepreneur Siphiwe Mabusela, is revolutionizing guest service with its innovative Mjumbe robot. Designed to operate seamlessly alongside human staff in restaurants and hotels, the Mjumbe robot not only serves food to guests but also enhances service efficiency by allowing staff to focus on personalized guest interactions. This integration of robotics into hospitality brings a new standard of service excellence, creating a unique dining experience that combines high-tech efficiency with personal warmth. Mjumbex’s cutting-edge approach to hospitality is setting a new benchmark, showcasing how robotics can enhance—not replace—human service.

Beyond product innovation, Siphiwe Mabusela’s Robotics and Coding Academy is shaping the future of tech education, dedicated to equipping young minds with critical skills in robotics, coding, and ethical AI. The academy’s curriculum spans essential tech skills to advanced topics such as human-robot collaboration and cloud integration. By offering hands-on learning experiences, Mabusela’s academy fosters a spirit of creativity, problem-solving, and innovation, ensuring that students are well-prepared for dynamic careers in the tech industry. With a mission to inspire and educate the next generation of tech innovators, the academy plays a pivotal role in nurturing talent for a digital future.

These three initiatives highlight the power of technology in driving meaningful change across industries. MineSafe360, Mjumbex, and the Robotics and Coding Academy are each contributing to a future where safety, efficiency, and education are enhanced by innovative, thoughtful applications of advanced technology.

Media Contact
Company Name: MineSafe360
Contact Person: Siphiwe Mabusela
Email:Send Email
Country: South Africa
Website: https://www.linkedin.com/in/siphiwemabusela

Acute Ischemic Stroke Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Acute Ischemic Stroke Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Acute Ischemic Stroke Research. Learn more about our innovative pipeline today! @ Acute Ischemic Stroke Pipeline Outlook

 

Key Takeaways from the Acute Ischemic Stroke Pipeline Report

• In November 2024:- Shanghai Hutchison Pharmaceuticals Limited- This study is a Phase II, multicenter, randomized, double Blind, placebo-Controlled design. Participants receive twice daily dosing for 7 consecutive days, or once on Days 1 and Day 8 and twice daily on Days 2 to Day 7, with each subject scheduled to receive 14 doses throughout the clinical trial. 270 Participants will be randomized 1:1:1 to SHPL-49 injection treated group (3 ampoules of SHPL-49 injections, BID), SHPL-49 injection treated group (6 ampoules of SHPL-49 injections , BID) and placebo group (BID).
• DelveInsight’s Acute Ischemic Stroke pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Acute Ischemic Stroke treatment.
• The leading Acute Ischemic Stroke Companies such as Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others.
• Promising Acute Ischemic Stroke therapies such as Sovateltide, Tenecteplase, BB-031, hUCB, LT3001, Elezanumab, Redasemtide, Cerebrolysin, SP-8203, and others.

 

Stay informed about the cutting-edge advancements in Acute Ischemic Stroke treatments. Download for updates and be a part of the revolution in care @ Acute Ischemic Stroke Clinical Trials Assessment

 

Acute Ischemic Stroke Emerging Drugs Profile

• Prourokinase recombinant: Tasly Pharmaceutical

Prourokinase recombinant, is an investigational drug being developed by Tasly Pharmaceutical for the treatment of Acute Ischemic Stroke. Recombinant human (rh) Pro-UK, is a novel type of thrombolytic, which preferentially activates plasminogen on the fibrin surface and induces fibrin-selective clot lysis. It has the advantages of more potent efficacy and less adverse reactions in comparison with other thrombolytics. Advantages of thrombolytic therapy using rhPro-UK for patients with acute myocardial infarction include its reliable curative effect and high safety. Currently, the drug is in the Phase III stage of its development for the treatment of Acute Ischemic Stroke.

• RNS60: Revalesio Corporation

RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. It activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the U.S. Food and Drug Administration. Currently, the drug is in the Phase II stage of its development for the treatment of Acute Ischemic Stroke.

• AVLX 144: Avilex Pharma

AVLX-144 is a dimeric peptide-like drug candidate for the treatment of AIS, which targets the intracellular scaffolding protein, PSD-95. AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor and a clinical lead candidate for the treatment of acute conditions such as AIS and subarachnoid hemorrhage (SAH). PSD-95 bridges the glutamate receptor subtype - the N-methyl-D-aspartate (NMDA) receptor and neuronal nitric oxide synthase (nNOS) via its two PDZ domains and AVLX-144 binds to both these PDZ domains simultaneously. The specific design of AVLX-144 provides several key advantages such as exceptionally high affinity to PSD-95, increased stability, and enhanced neuroprotective properties. Currently, the drug is in the Phase I stage of its development for the treatment of Acute Ischemic Stroke.

 

Learn more about Acute Ischemic Stroke Drugs opportunities in our groundbreaking Acute Ischemic Stroke Research and development projects @ Acute Ischemic Stroke Unmet Needs

 

Acute Ischemic Stroke Companies

Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others

 

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Acute Ischemic Stroke Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Acute Ischemic Stroke Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Discover the latest advancements in Acute Ischemic Stroke treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Acute Ischemic Stroke Market Drivers and Barriers, and Future Perspectives

 

Scope of the Acute Ischemic Stroke Pipeline Report

• Coverage- Global
• Acute Ischemic Stroke Companies such as Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others.
• Acute Ischemic Stroke Therapies- Sovateltide, Tenecteplase, BB-031, hUCB, LT3001, Elezanumab, Redasemtide, Cerebrolysin, SP-8203, and others.
• Acute Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Acute Ischemic Stroke Pipeline on our website @ Acute Ischemic Stroke Emerging Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Acute Ischemic Stroke: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Ischemic Stroke– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Enzastaurin: Denovo BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MDNA55: Medicenna Therapeutics, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Zotiraciclib: Adastra Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RGN6024: Reglagene, Inc.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Acute Ischemic Stroke Key Companies
21. Acute Ischemic Stroke Key Products
22. Acute Ischemic Stroke- Unmet Needs
23. Acute Ischemic Stroke- Market Drivers and Barriers
24. Acute Ischemic Stroke- Future Perspectives and Conclusion
25. Acute Ischemic Stroke Analyst Views
26. Acute Ischemic Stroke Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/